NVCT
Nuvectis Pharma, Inc.BS score 42.0LOWPHASE1 · mkt cap $216.2M · rev ttm $0
drug hypothesis
NXP800 modulates Not specified in provided filing data to treat Advanced solid tumors, ovarian cancer (including ovarian clear cell carcinoma, ovarian endometrioid adenocarcinoma, ARID1A mutation-positive cancers).
moa:Not specified in provided filing data
score breakdown
trial design70
base rate disconnect25
language red flags20
composite42.0
valuation analysis
market cap$216.2M
revenue ttm$0
phasePHASE1
historical base rate5%
disconnect ratio0.9x
lead trialNCT05873686
meta
cik0001875558
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 1, non-randomized, single-arm study in subjects with advanced cancers with expansion cohort in ovarian cancer. Enrollment of 45 patients. Part A dose escalation to determine safety and tolerability. Secondary endpoints include PK parameters (AUC, Cmax, Tmax, T1/2).
primary endpoint:Part A: Number of patients with treatment related adverse events, clinical laboratory abnormalities, dose limiting toxicities (Day 28)
claimed differentiation
Not provided in available data
language red flags
- Insufficient data provided to assess - only clinical trial registry data (NCT05226507) available, no actual SEC filing text with business section details was included in the request